A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome

Trial Profile

A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2018

At a glance

  • Drugs GLWL 01 (Primary)
  • Indications Prader-Willi syndrome
  • Focus Therapeutic Use
  • Sponsors GLWL Research
  • Most Recent Events

    • 21 Aug 2018 Planned End Date changed from 17 Dec 2018 to 1 Feb 2019.
    • 21 Aug 2018 Planned primary completion date changed from 17 Dec 2018 to 1 Feb 2019.
    • 26 Jun 2018 Planned End Date changed from 14 Sep 2018 to 17 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top